Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal in the space of a week.BMS is paying $62.50 per share in cash for San Diego-based RayzeBio and its pipeline of radiopharmaceuticals for solid tumours – including a late-stage candidate […]
